Eris Lifesciences Balance Sheet Health
Financial Health criteria checks 5/6
Eris Lifesciences has a total shareholder equity of ₹24.3B and total debt of ₹8.3B, which brings its debt-to-equity ratio to 34.2%. Its total assets and total liabilities are ₹38.8B and ₹14.5B respectively. Eris Lifesciences's EBIT is ₹4.8B making its interest coverage ratio 8.3. It has cash and short-term investments of ₹1.9B.
Key information
34.2%
Debt to equity ratio
₹8.30b
Debt
Interest coverage ratio | 8.3x |
Cash | ₹1.91b |
Equity | ₹24.28b |
Total liabilities | ₹14.48b |
Total assets | ₹38.75b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 540596's short term assets (₹9.6B) exceed its short term liabilities (₹5.0B).
Long Term Liabilities: 540596's short term assets (₹9.6B) exceed its long term liabilities (₹9.5B).
Debt to Equity History and Analysis
Debt Level: 540596's net debt to equity ratio (26.3%) is considered satisfactory.
Reducing Debt: 540596's debt to equity ratio has increased from 26.5% to 34.2% over the past 5 years.
Debt Coverage: 540596's debt is well covered by operating cash flow (53.6%).
Interest Coverage: 540596's interest payments on its debt are well covered by EBIT (8.3x coverage).